Dermata Therapeutics, Inc. (DRMA)
1.21
-0.02
(-1.63%)
USD |
NASDAQ |
Sep 04, 16:00
1.24
+0.03
(+2.48%)
After-Hours: 20:00
Dermata Therapeutics Enterprise Value : 0.4539M for Sept. 4, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 04, 2026 | 0.4539M |
| September 03, 2026 | 0.5344M |
| September 02, 2026 | 0.7355M |
| September 01, 2026 | 0.8159M |
| August 31, 2026 | 0.7757M |
| August 28, 2026 | 0.9768M |
| August 27, 2026 | 1.460M |
| August 26, 2026 | 2.063M |
| August 25, 2026 | 2.505M |
| August 24, 2026 | 2.143M |
| August 21, 2026 | 1.299M |
| August 20, 2026 | 1.138M |
| August 19, 2026 | 1.500M |
| August 18, 2026 | 1.339M |
| August 17, 2026 | 1.460M |
| August 14, 2026 | 1.460M |
| August 13, 2026 | 1.902M |
| August 12, 2026 | 1.138M |
| August 11, 2026 | -0.0689M |
| August 10, 2026 | 0.092M |
| August 07, 2026 | 0.0115M |
| August 06, 2026 | 0.0517M |
| August 05, 2026 | 0.2931M |
| August 04, 2026 | 0.0115M |
| August 03, 2026 | -0.089M |
| Date | Value |
|---|---|
| July 31, 2026 | 0.2931M |
| July 30, 2026 | 0.3333M |
| July 29, 2026 | 0.3333M |
| July 28, 2026 | 0.5545M |
| July 27, 2026 | 0.7757M |
| July 24, 2026 | 0.8964M |
| July 23, 2026 | 0.655M |
| July 22, 2026 | 0.655M |
| July 21, 2026 | 0.7355M |
| July 20, 2026 | 0.6953M |
| July 17, 2026 | 0.9366M |
| July 16, 2026 | 0.7355M |
| July 15, 2026 | 0.8159M |
| July 14, 2026 | 0.8964M |
| July 13, 2026 | 1.017M |
| July 10, 2026 | 0.9768M |
| July 09, 2026 | 0.9768M |
| July 08, 2026 | 1.218M |
| July 07, 2026 | 1.258M |
| July 06, 2026 | 0.9768M |
| July 02, 2026 | 0.9768M |
| July 01, 2026 | 1.138M |
| June 30, 2026 | 0.7757M |
| June 29, 2026 | -1.717M |
| June 26, 2026 | -1.757M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 265.34M |
| Perspective Therapeutics, Inc. | 124.18M |
| MiMedx Group, Inc. | 547.33M |
| ABVC BioPharma, Inc. | 29.52M |
| Endonovo Therapeutics, Inc. | 7.194M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.967M |
| Total Expenses (Quarterly) | 2.967M |
| EPS Diluted (Quarterly) | -0.7377 |
| Earnings Yield | -362.5% |
| Normalized Earnings Yield | -362.51 |